Subcutaneous immunoglobulin offers a number of advantages over IVIG. Systemic adverse events including malaise, fever and headache are very infrequent with SCIG, which can particularly help those who find themselves struggling around the time of IVIG with these symptoms. Flexibility in administration is another advantage as SCIG can be self-administered at home usually once or twice a week as opposed to monthly hospital visits required for IVIG as home-IVIG is not available in Canada at this time. Difficulty with venous access for patients with chronic neuromuscular conditions requiring frequent intravenous treatment can also be a potentially limiting factor which SCIG can bypass. Although many patients with chronic neuromuscular disorders have challenges with strength, sensation and dexterity, most patients will be able to perform the physical requirements of subcutaneous infusion either on their own or with assistance from a caretaker or family member. From a Canadian health systems perspective, switching from IVIG to SCIG in patients requiring chronic treatment frees up valuable space and time in hospital infusion centers where intravenous blood products are usually administered.
It remains to be seen how this newly available treatment will fit in the treatment algorithm of patients with chronic immune neurological conditions. Most studies including the one presented in this issue of the journal indicate that a proportion of patients will not be able to maintain stability on SCIG and require intermittent IVIG treatment or an outright switch back to intravenous immunoglobulin treatment. Although most patients can tolerate the expected, mild, transient skin reactions that usually occur in patients receiving SCIG, some patients may experience more serious local reactions which may limit longterm tolerability and retention. Although some studies including Suleman et al have evaluated patients over at least 12 months, many other studies to date present short-term outcomes. Evaluation of trial patients through open-label extensions or post-marketing surveillance in patients starting SCIG outside a clinical trial will be of key importance going forward in order to capture the long-term viability of SCIG as a treatment in neurological disease. Finally, although the current evidence provides a range of SCIG doses that appear to be tolerated and efficacious in patients with neuromuscular diseases, the ideal dosing and duration of treatment in each neuromuscular disease from a clinical and pharmacoeconomic perspective also remains unknown and a recommended area for future research.
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